Jones Financial Companies
NKTR icon

Jones Financial Companies’s Nektar Therapeutics NKTR Stock Holding History

Jones Financial Companies’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.6K Buy
300
+191
+175% +$10.9K ﹤0.01% 3281
2025
Q4 		$4.61K Sell
109
-6
-5% -$336 ﹤0.01% 3541
2025
Q3 		$6.73K Buy
115
+22
+24% +$728 ﹤0.01% 3247
2025
Q2 		$2.4K Buy
93
+33
+55% +$371 ﹤0.01% 3407
2025
Q1 		$668 Buy
60
+33
+122% +$431 ﹤0.01% 3476
2024
Q4 		$372 Buy
+27
New +$476 ﹤0.01% 3262

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Jones Financial Companies's NKTR Position: Q1 2026 in Review

Jones Financial Companies increased its Nektar Therapeutics (NKTR) stake by 175% in Q1 2026, buying an estimated $10.9K and bringing the position to 300 shares worth $20.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3281.

Jones Financial Companies first reported a position in NKTR in Q4 2024 and has held it in 6 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Jones Financial Companies held 300 shares of Nektar Therapeutics worth $20.6K as of Q1 2026.
  • Jones Financial Companies bought 191 Nektar Therapeutics shares in Q1 2026, an estimated $10.9K.
  • Nektar Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q1 2026, its #3281 holding.
  • Jones Financial Companies first reported a position in Nektar Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Jones Financial Companies's 13F filing for Q1 2026, filed 15 May 2026.